Imipramine, in part through tumor necrosis factor α inhibition, prevents cognitive decline and β-amyloid accumulation in a mouse model of Alzheimer's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 505-514

  Chavant, F ^a,b   Deguil, J ^a   Pain, S ^a,b   Ingrand, I ^a,b   Milin, S ^a,b   Fauconneau, B ^a,b   Perault Pochat M C ^a,b   Lafay Chebassier, C ^a,b  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; IMIPRAMINE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXPERIMENTAL MOUSE; FRONTAL CORTEX; HIPPOCAMPUS; LONG TERM MEMORY; MALE; MAZE TEST; MEMORY DISORDER; MODULATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT TERM MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HIPPOCAMPUS; IMIPRAMINE; INJECTIONS, INTRAVENTRICULAR; MALE; MEMORY; MEMORY DISORDERS; MICE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76749163675     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162164     Document Type: Article

References (40)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
2. Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K, and Nabeshima T (2008) Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 189:100-106.
3. Baune BT, Wiede F, Braun A, Golledge J, Arolt V, and Koerner H (2008) Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet 147B:1056-1064.
4. Belleville S, Peretz I, and Malenfant D (1996) Examination of the working memory components in normal aging and in dementia of the Alzheimer type. Neuropsychologia 34:195-207.
5. Blasko I, Marx F, Steiner E, Hartmann T, and Grubeck-Loebenstein B (1999) TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13:63-68.
6. Burt DB, Zembar MJ, and Niederehe G (1995) Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 117: 285-305.
7. Calev A, Ben-Tzvi E, Shapira B, Drexler H, Carasso R, and Lerer B (1989) Distinct memory impairments following electroconvulsive therapy and imipramine. Psychol Med 19:111-119.
8. Dredge K, Connor TJ, Kelly JP, and Leonard BE (1999) Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1beta and tumor necrosis factor-alpha secretion following an in vivo lipopolysaccharide challenge in rats. Int J Immunopharmacol 21:663-673.
9. Fiore M, Angelucci F, Alleva E, Branchi I, Probert L, and Aloe L (2000) Learning performances, brain NGF distribution and NPY levels in transgenic mice expressing TNF-alpha. Behav Brain Res 112:165-175.
10. Frewer LJ and Lader M (1993) The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 8:13-20.
11. Giuliani F, Vernay A, Leuba G and Schenk F (2009) Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism. Brain Res Bull 80:302-308.
12. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, and Shen Y (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178:829-841.
13. Huang YY, Peng CH, Yang YP, Wu CC, Hsu WM, Wang HJ, Chan KH, Chou YP, Chen SJ, and Chang YL (2007) Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 104:61-72.
14. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW, Lee WH, Park HC, and Suk K (2008) Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 55:826-834.
15. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, and Bowers WJ (2005) Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2:23.
16. Kuo LH, Hu MK, Hsu WM, Tung YT, Wang BJ, Tsai WW, Yen CT, and Liao YF (2008) Tumor necrosis factor-alpha-elicited stimulation of gamma-secretase is mediated by c-Jun N-terminal kinase-dependent phosphorylation of presenilin and nicastrin. Mol Biol Cell 19:4201-4212.
17. Li R, Yang L, Lindholm K, Konishi Y, Yue X, Hampel H, Zhang D, and Shen Y (2004) Tumor necrosis factor death receptor signaling cascade is required for amyloidbeta protein-induced neuron death. J Neurosci 24:1760-1771.
18. 25-35 peptide-induced memory impairments: Implication of inducible nitric oxide synthase and tumor necrosis factor-α in mice. J Pharmacol Exp Ther 331:319-326.
19. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, Ikejima T, and Nabeshima T (2009b) Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 157:1270-1277.
20. Maurice T, Lockhart BP, and Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181-193.
21. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, et al. (2009) Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 34:163-177.
22. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Di Giunta G, Figueiredo CP, Takahashi RN, et al. (2007) Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27:5394-5404.
23. Morris RG, Garrud P, Rawlins JN, and O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683.
24. Naudon L, Hotte M, and Jay TM (2007) Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. Psychopharmacology (Berl) 191:353-364.
25. Pákáski M, Bjelik A, Hugyecz M, Kása P, Janka Z, and Kálmán J (2005) Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 47:190-195.
26. Peselow ED, Corwin J, Fieve RR, Rotrosen J, and Cooper TB (1991) Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 21:173-183.
27. Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, Jaffuel D, and Mathieu M (2007) Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 8:35.
28. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
29. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, and Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382:120-121.
30. Song L, Che W, Min-Wei W, Murakami Y, and Matsumoto K (2006) Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 83:186-193.
31. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, and Mullan M (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286:2352-2355.
32. Teri L, Reifler BV, Veith RC, Barnes R, White E, McLean P, and Raskind M (1991) Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46:P372-P377.
33. Tobinick E, Gross H, Weinberger A, and Cohen H (2006) TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8:25.
34. Tobinick EL and Gross H (2008) Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 5:2.
35. Tousoulis D, Drolias A, Antoniades C, Vasiliadou C, Marinou K, Latsios G, Stefanadi E, Gounari P, Siasos G, Papageorgiou N, et al. (2009) Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int J Cardiol 134:238-243.
36. Walsh DM and Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
37. Wang Q, Wu J, Rowan MJ, and Anwyl R (2005) Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22:2827-2832.
38. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005-1015.
39. Xu Y, Lin D, Li S, Li G, Shyamala SG, Barish PA, Vernon MM, Pan J, and Ogle WO (2009) Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress. Neuropharmacology 57:463-471.
40. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, and Ikezu T (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170:680-692.